反应详情

The title compound was prepared in analogy to the procedure described in Example 110 using 4-(4-chlorophenyl)-3-methyl-1-(1-methyl-1H-pyrazol-5-yl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one (Step 114.2) and 6-chloro-3,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine (Step 111.2). The crude material was first purified by silica gel column chromatography (CH2Cl2/MeOH 1-5%), followed by preparative achiral SFC (column NH2, gradient 9-14% in 6 min_total 11 min) and trituration in Et2O. tR: 4.37 min (HPLC 1); tR: 1.01 min (LC-MS 2); ESI-MS: 474 [M+H]+ (LC-MS 2); ESI-MS: 472 [M−H]− (LC-MS 2); Rf=0.45 (CH2Cl2/MeOH 9:1); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.05 (s, 3H) 2.53 (s, 3H) 2.56 (s, 3H) 3.85 (s, 3H) 6.60 (s, 1H) 6.65 (d, J=2.0 Hz, 1H) 7.39 (d, J=8.2 Hz, 2H) 7.54-7.60 (m, 3H) 8.02-8.05 (m, 1H).

1. customThe crude material was first purified by silica gel column chromatography (CH2Cl2/MeOH 1-5%)
2. customfollowed by preparative achiral SFC (column NH2, gradient 9-14% in 6 min_total 11 min) and trituration in Et2O